Products that are naturally positioned, science backed, and effortless to integrate into everyday routines will be especially important, helping consumers support their health goals in a simple and reassuring way. Gateway Health Alliances Kothari also anticipates beverages to play a larger role in the future of GLP-1 medications
What the Current Evidence Says About Long-Term Outcomes Phase 2 data show substantial short-term weight loss with retatrutide, but long-term evidence beyond 48 weeks is limited
Reference: Gasoyan H, Butsch WS, Schulte R, et al
But, if you have access to both, we would recommend the following: If your health would benefit from the higher percentage weight loss (15-20%) of Zepbound / tirzepatide, and you have not had a cardiac event, Zepbound offers modestly more weight loss with fewer side effects